Arena sells off Belviq rights

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said it amended its licensing agreement with Eisai Co. Ltd. (Tokyo:4523), granting the

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE